Ask about this productRelated genes to: IL1a protein (Mouse)
- Gene:
- IL1A NIH gene
- Name:
- interleukin 1 alpha
- Previous symbol:
- IL1
- Synonyms:
- IL1F1, IL-1A, IL1-ALPHA
- Chromosome:
- 2q14.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-05
Related products to: IL1a protein (Mouse)
Related articles to: IL1a protein (Mouse)
- Lung transplantation (LTx) is associated with an increased risk of infection, causing notable morbidity and mortality at all phases post-transplantation. The contribution of host-related immune factors to susceptibility to post-LTx infections is not fully understood. - Source: PubMed
Publication date: 2026/05/01
Kufa JiriSchneiderova PetraGenzor SamuelTrajerova MarketaJakubec PetrMizera JanZurkova MonikaKriegova Eva - Tuberculosis (TB) is a chronic infectious disease caused by (), and poses a significant threat to global human health. Dendritic cells (DCs) represent the most potent antigen-presenting cells and play a critical role in host defenses against infection. - Source: PubMed
Publication date: 2026/04/13
Sun XiaohongBao ShuangshuangZhou KaixinSun YaqiGao QianLin Yan - Idiopathic retroperitoneal fibrosis (iRPF) is a rare disease frequently misdiagnosed due to the lack of reliable biomarkers. This study aimed to identify novel autoantibodies to improve the diagnosis and differential diagnosis of iRPF. - Source: PubMed
Publication date: 2026/04/28
He XiOuyang LizhiMeng XinyuWu YiweiWu TongxinHe ZhengtingYang JinmingZhu XinyunXuan HanqingSong RuiCao ShanChen Xiaoxiang - Ovarian cancer is the most lethal gynecological malignancy worldwide, largely due to late diagnosis and lack of effective population-level screening tools. Inflammatory cytokines regulate proliferation, apoptosis, angiogenesis, and immune surveillance, making inherited variation in cytokine pathways biologically plausible determinants of ovarian cancer susceptibility and progression. Since the early 2000s, numerous candidate-gene studies have evaluated polymorphisms of genes such as the interleukin () families, tumor necrosis factor alpha (), transforming growth factor beta 1 (), and components of the nuclear factor kappa B () signaling pathway and adhesion pathways, across diverse populations. In this review, we summarize these potential markers to give readers an overview showing accumulated evidence supports a coherent model in which genetically modulated inflammation is an integral driver of epithelial ovarian carcinogenesis. Collectively, studies reveal recurrent patterns of risk-increasing and risk-protective variants. Risky genotypes predicted to enhance pro-inflammatory, pro-angiogenic, or immunosuppressive signaling include rs16944 CC, rs1800795, rs2227306 TT, rs1126647 TT, rs11556218 GT/GG, rs4778889 CT/CC, rs10889677 AC/CC, rs4758680 CA/AA, rs28372698 TT, rs1800629 GA/AA, and peroxisome proliferator-activated receptor gamma () rs1801282 CG genotypes. Conversely, protective variants tend to dampen inflammatory tone or rebalance cytokine networks, including rs17561 GT/TT, rs4848300 CT/CC, rs3783553 insertion/insertion, rs7596684 CT/CC, rs1880242 GT/TT, rs7977932 CG/GG, rs1800469 CT/TT, selectin E () rs5361 AC, intercellular adhesion molecule 1 () rs5498 AG genotypes and specific haplotypes. Beyond risk , several polymorphisms appear predictive of clinical features, including tumor stage, cytoreductive resectability and recurrence, highlighting potential prognostic relevance. Notably, associations are often population-specific, reflecting differences in allelic frequencies and linkage disequilibrium across ethnic groups, underscoring the need for cross-ethnic replication. Further investigations may ultimately enable further improved the prevention, early detection, and personalized management of ovarian cancer. - Source: PubMed
Chang Wen-ShinTsai Chia-WenChen Jaw-ChyunWang Yun-ChiBau DA-Tian - Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a 5-year survival rate of only 12%, driven by late diagnosis, rapid metastasis, and an immunosuppressive tumor microenvironment (TME). Current therapies, including chemotherapy and immune checkpoint blockade, show limited efficacy due to the "cold" TME. Interleukin-1α (IL-1α) plays a central role in PDAC progression. TCGA (n = 178) and ICGC (n = 267) analyses reveal that high IL1A expression independently predicts poor overall survival (HR = 1.99, 95% CI 1.01-3.93) and progression-free survival (HR = 3.11, 95% CI 1.24-7.80). As a biomarker, IL-1α outperforms traditional CA19-9 for risk stratification and treatment selection. Its detection in serum and exosomes supports potential applications in liquid biopsy for early detection. Therapeutically, IL-1α blockers using agents such as anakinra, canakinumab, and nadunolimab show synergy with immune checkpoint inhibitors and chemotherapy. This combination has been evaluated in preclinical models and early-phase clinical trials. It achieves disease control rates of up to 62% and median progression-free survival of up to 6.8 months, while also reducing fibrosis and enhancing antitumor immunity. This review synthesizes the critical role of interleukin-1α (IL-1α) in PDAC pathogenesis and its potential implications for immunotherapy and molecular biomarker development. IL-1α is highly expressed in PDAC tumor cells and tumor-associated macrophages (TAMs). It activates the NF-κB and MAPK pathways, thereby promoting epithelial-mesenchymal transition (EMT), stromal fibrosis, and immunosuppression. This includes the recruitment of neutrophils and myeloid-derived suppressor cells (MDSCs), which collectively maintain an immunosuppressive ('cold') tumor microenvironment (TME) and contribute to therapeutic resistance. Future multi-omics stratification, targeted delivery systems, and rational combination strategies hold promise for improving PDAC outcomes. - Source: PubMed
Publication date: 2026/04/25
Ling KeXie GuangfeiChen ZeDa MingxuQiu Zhisheng